All In Biotech

Free tool

FAERS Monitor: Saxenda

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206321 or its brand name (Saxenda, Liraglutide). Reports on generic versions are filed under their own applications.

Reports

10,421

Serious

5,921

57% of reports

Hospitalization

2,523

Death reported

297

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea1,390
  • vomiting809
  • diarrhoea566
  • drug ineffective546
  • off label use518
  • weight increased447
  • fatigue439
  • headache435
  • constipation408
  • dyspnoea408
  • anxiety344
  • weight loss poor339
  • condition aggravated323
  • decreased appetite312
  • dizziness312

Reports by year received

View as table
YearReports
20081
20092
201014
201119
201230
201340
201459
2015359
20161,262
20171,041
2018616
2019805
2020719
2021799
2022814
20231,040
2024863
2025909
20261,029

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,738 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
weight loss poorSignal339143.2128.544,590
weight increasedSignal4474.03.71,026
constipationSignal4083.83.4839
nauseaSignal1,3903.53.42,637
vomitingSignal8093.53.31,455
decreased appetiteSignal3122.72.4339
anxietySignal3442.42.2295
condition aggravatedSignal3232.11.9199
diarrhoea5661.81.6195
dyspnoea4081.51.359
headache4351.41.351
dizziness3121.31.117
off label use5181.21.117
fatigue4391.11.07
drug ineffective5460.80.819

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.